

TABLE OF CONTENTS

0. Executive Summary	20
1. Basic Aspects.....	22
Definition of personalized medicine	22
History of medical concepts relevant to personalized medicine	23
Molecular biological basis of personalized medicine	25
The human genome	25
Chromosomes	26
Genes.....	26
<i>The genetic code.....</i>	26
<i>Gene expression</i>	27
<i>DNA sequences and structure</i>	27
Genetic variations in the human genome	27
<i>Single nucleotide polymorphisms</i>	28
<i>Copy number variations in the human genome</i>	28
<i>Insertions and deletions in the human genome</i>	30
<i>Large scale variation in human genome</i>	31
<i>Structural variations in the human genome</i>	31
<i>Mapping and sequencing of structural variation from human genomes</i>	31
<i>1000 Genomes Project.....</i>	32
<i>Role of DNA sequencing in the development of personalized medicine</i>	34
<i>Human Variome Project</i>	34
<i>Interconnected genetic and genomic patterns in human diseases.....</i>	34
Basics technologies for developing personalized medicine	35
Definitions of technologies relevant to personalized medicine	35
Problems with the ICH definitions of pharmacogenomics and pharmacogenetics	36
Relationship of various technologies to personalized medicine	36
Conventional medicine versus personalized medicine	37
Role of genetics in future approaches to healthcare	37
Genetic medicine	37
Human disease and genes.....	37
Genetic and environmental interactions in etiology of human diseases.....	38
Role of genetics in development of personalized medicines.....	38
<i>Genetic databases.....</i>	39
<i>Genetic epidemiology</i>	39
<i>Limitations of medical genetics and future prospects</i>	39
<i>Genetics vs. epigenetics.....</i>	40
Role of systems biology in personalized medicine	40
Systems pharmacology	41
Systems medicine	42
Synthetic biology and development of personalized medicines.....	43
A personalized approach to environmental factors in disease.....	43
Reclassification of diseases	44
2. Molecular Diagnostics in Personalized Medicine	46
Introduction.....	46
Molecular diagnostic technologies	46
PCR-based methods	47
<i>DirectLinear™ Analysis</i>	47
<i>Denaturing high-performance liquid chromatography.....</i>	48
<i>Multiplex Allele-Specific Diagnostic Assay.....</i>	48
<i>Representational oligonucleotide microarray analysis.....</i>	48
<i>Restriction fragment length polymorphism (RFLP)</i>	48
<i>Real-time PCR for detection of CNVs.....</i>	48
Non-PCR methods	49
<i>Arrayed primer extension (APEX)</i>	49
<i>Enzymatic Mutation Detection (EMD)</i>	49
DNA sequencing.....	49
<i>Sanger-sequencing technology</i>	50
<i>ABI PRISM® 310 Genetic Analyzer.....</i>	51
<i>High-throughput paired end transcriptome sequencing</i>	51
Emerging sequencing technologies	51
<i>4300 DNA analyzer</i>	52
<i>Apollo 100.....</i>	52
<i>"Color blind" approach to DNA sequencing</i>	53
<i>Cyclic array sequencing</i>	53
<i>CEQ™ 8000.....</i>	53

DeepCAGE sequencing	53
Electron microscope-based DNA sequencing	54
Genometrica™ sequencer	54
GS-FLEX system (Roche/454)	55
IBS sequencing technology	56
Illumina Genome Analyzer System	56
MegaBACE 500	57
Microdroplet-based PCR for large-scale targeted sequencing	57
Multiplex amplification of human DNA sequences	58
Nanoscale sequencing	58
Polonator sequencer	58
RainStorm™ microdroplet technology	59
Sequential DEXAS	59
SOLiD technology	60
Sequencing by hybridization	61
Whole genome sequencing	61
Bioinformatic tools for analysis of genomic sequencing data	61
Detection of single molecules in real time	62
Direct observation of nucleotide incorporation	62
Molecular Combing	62
Nanopore sequencing	62
DNA sequence by use of nanoparticles	63
Zero-mode waveguide nanostructure arrays	63
Future prospects of sequencing	63
Role of sequencing in development of personalized medicine	64
Biochips and microarrays	65
Application of biochip technology in developing personalized medicine	65
Standardizing the microarrays	66
Biochip technologies	66
GeneChip	67
AmpliChip CYP450	67
Microfluidics	68
Lab-on-a-chip	69
Micronics' microfluidic technology	69
LabCD	69
Microfluidic automated DNA analysis using PCR	70
Integrated microfluidic bioassay chip	70
Electronic detection of nucleic acids on microarrays	70
Strand displacement amplification on a biochip	71
Rolling circle amplification on DNA microarrays	71
Universal DNA microarray combining PCR and ligase detection reaction	71
Protein biochips	72
ProteinChip	72
LabChip for protein analysis	73
TRINECTIN proteome chip	73
Protein expression microarrays	74
Microfluidic devices for proteomics-based diagnostics	74
New developments in protein biochips/microarrays	74
Protein biochips/microarrays for personalized medicine	75
SNP genotyping	75
Genotyping and haplotyping	76
Haplotype Specific Extraction	77
Computation of haplotypes	77
HapMap project	78
Haplotyping for whole genome sequencing	79
Predicting drug response with HapMap	79
Companies developing haplotyping technology	79
Technologies for SNP analysis	80
Biochip and microarray-based detection of SNPs	81
SNP genotyping by MassARRAY	81
Biochip combining BeadArray and ZipCode technologies	81
SNP-IT primer-extension technology	82
Affymetrix Variation Detection Arrays	82
Use of NanoChip for detection of SNPs	82
Electrochemical DNA probes	83
Single base extension-tag array	83
Laboratory Multiple Analyte Profile	83
PCR-CTPP (confronting two-pair primers)	84
SNP genotyping on a genome-wide amplified DOP-PCR template	84
TaqMan real-time PCR	84
Non-Enzymatic Amplification Technology	84

SNP genotyping with gold nanoparticle probes.....	85
Locked nucleic acid	85
Molecular inversion probe based assays	85
Pyrosequencing	86
Reversed enzyme activity DNA interrogation test	86
Smart amplification process version 2.....	87
Zinc finger proteins	87
UCAN method (Takara Biomedical).....	87
Mitochondrial SNPs.....	88
Limitations of SNP in genetic testing.....	88
Concluding remarks on SNP genotyping	88
Companies involved in developing technologies/products for SNP analysis	89
Impact of SNPs on personalized medicine	90
Detection of copy number variations	91
Study of rare variants in pinpointing disease-causing genes	91
Optical Mapping	92
Role of nanobiotechnology in molecular diagnostics	92
Cantilevers for personalized medical diagnostics	93
Nanopore-based technology for single molecule identification	93
Role of biomarkers in personalized medicine	94
Biomarkers for diagnostics	94
Biomarkers for drug development	95
Application of proteomics in molecular diagnosis	95
Proteomic strategies for biomarker identification	95
<i>Proteomic technologies for detection of biomarkers in body fluids</i>	<i>95</i>
Protein patterns	96
Layered Gene Scanning	96
Comparison of proteomic and genomic approaches in personalized medicine	97
Gene expression profiling	97
DNA microarrays.....	98
Analysis of single-cell gene expression.....	98
Gene expression profiling based on alternative RNA splicing	99
Whole genome expression array	100
Tangerine™ expression profiling	100
Gene expression analysis on biopsy samples	101
Profiling gene expression patterns of white blood cells	101
Serial analysis of gene expression (SAGE).....	102
Multiplexed Molecular Profiling	102
Gene expression analysis using competitive PCR and MALDI TOF MS	103
Monitoring in vivo gene expression by magnetic resonance imaging	103
Companies involved in gene expression analysis	103
Monitoring in vivo gene expression by molecular imaging	104
Molecular imaging and personalized medicine	105
Glycomics-based diagnostics	105
Combination of diagnostics and therapeutics.....	105
Use of molecular diagnostics for stratification in clinical trials	106
Companion diagnostics	106
Companies involved in companion diagnostics	106
Point-of-care diagnosis	108
Companies developing point-of-care diagnostic technologies	109
Point-of-care diagnosis of infections	111
Advantages versus disadvantages of point-of-care diagnosis	112
Future prospects of point-of-care diagnosis	112
Genetic testing for disease predisposition	113
Preventive genetics by early diagnosis of mitochondrial diseases	113
Direct-to-consumer genetic services.....	113
Role of diagnostics in integrated healthcare	115
Concept of integrated healthcare	115
Components of integrated healthcare	116
<i>Screening.....</i>	<i>116</i>
<i>Disease prediction</i>	<i>116</i>
<i>Early diagnosis</i>	<i>116</i>
<i>Prevention.....</i>	<i>116</i>
<i>Therapy based on molecular diagnosis</i>	<i>116</i>
<i>Monitoring of therapy</i>	<i>116</i>
Advantages and limitations of integrated healthcare.....	117
Commercially available systems for integrated healthcare	117
Future of molecular diagnostics in personalized medicine	118
3. Pharmacogenetics	120
Basics of pharmacogenetics	120

Role of molecular diagnostics in pharmacogenetics	121
Role of pharmacogenetics in pharmaceutical industry	122
Study of the drug metabolism and pharmacological effects	122
Causes of variations in drug metabolism	122
Enzymes relevant to drug metabolism	123
Pharmacogenetics of phase I metabolism	123
CYP450.....	123
P450 CYP 2D6 inhibition by selective serotonin reuptake inhibitors.....	125
Cytochrome P450 polymorphisms and response to clopidogrel.....	126
Lansoprazole and cytochrome P450.....	126
Glucose-6-phosphate dehydrogenase	126
Pharmacogenetics of phase II metabolism.....	127
N-Acetyltransferase.....	127
Uridine diphosphate-glucuronosyltransferase.....	128
Measurement of CYP isoforms.....	128
Polymorphism of drug transporters	129
Genetic variation in drug targets.....	129
Polymorphisms of kinase genes	130
Effect of genetic polymorphisms on disease response to drugs.....	130
Ethnic differences in drug metabolism	131
Gender differences in pharmacogenetics	131
Role of pharmacogenetics in drug safety	132
Adverse drug reactions	132
Adverse drug reactions in children.....	133
Adverse drug reactions related to toxicity of chemotherapy.....	133
Genetically determined adverse drug reactions	133
Malignant hyperthermia	135
Pharmacogenetics of clozapine-induced agranulocytosis.....	135
Role of pharmacogenetics in warfarin therapy.....	135
Role of pharmacogenetics in antiplatelet therapy	136
Role of pharmacogenetics in carbamazepine therapy	138
Role of pharmacogenetics in statin therapy	138
FDA consortium linking genetic biomarkers to serious adverse events.....	139
Therapeutic drug monitoring, phenotyping, and genotyping	139
Therapeutic drug monitoring	140
Phenotyping	140
Genotyping	141
Genotyping vs phenotyping.....	141
Phenomics	142
Limitations of genotype-phenotype association studies	143
Molecular toxicology in relation to personalized medicines.....	143
Toxicogenomics	143
Biomarkers of drug toxicity	143
Drug-induced mitochondrial toxicity	144
Companies involved in molecular toxicology	144
Gene expression studies	145
Pharmacogenetics in clinical trials	145
Postmarketing pharmacogenetics.....	146
Clinical implications of pharmacogenetics	146
Application of CYP450 genotyping in clinical practice.....	146
Pharmacogenomic biomarker information in drug labels.....	146
Genotype-based drug dose adjustment.....	147
Examples of use of pharmacogenetics in clinical pharmacology	147
Genotyping for identifying responders to sulfasalazine	147
HLA alleles associated with lumiracoxib-related liver injury.....	147
Pharmacogenetic basis of thiopurine toxicity.....	148
Tranilast-induced hyperbilirubinemia due to gene polymorphism	148
Linking pharmacogenetics with pharmacovigilance	148
Genetic susceptibility to ADRs.....	148
Linking genetic testing to postmarketing ADR surveillance.....	149
Recommendations for the clinical use of pharmacogenetics	149
Limitations of pharmacogenetics	150
Pharmacoepigenomics vs pharmacogenetics in drug safety	150
Future role of pharmacogenetics in personalized medicine	151
4. Pharmacogenomics	152
Introduction	152
Basics of pharmacogenomics	153
Pharmacogenomics and drug discovery	153
Preclinical prediction of drug efficacy	155
Pharmacogenomics and clinical trials	155

Impact of genetic profiling on clinical studies.....	156
Limitations of the pharmacogenomic-based clinical trials.....	157
Pharmacogenomic aspects of major therapeutic areas	158
Oncogenomics	158
<i>Oncogenes</i>	158
<i>Tumor suppressor genes</i>	159
Cardiogenomics	160
Neuropharmacogenomics.....	162
<i>Pharmacogenomics of Alzheimer's disease</i>	162
<i>Pharmacogenomics of depression</i>	163
<i>Pharmacogenomics of schizophrenia</i>	163
<i>Companies involved in neurogenomics-based drug discovery</i>	164
5. Role of Pharmacoproteomics	166
Basics of proteomics	166
Proteomic approaches to the study of pathophysiology of diseases.....	166
Single cell proteomics for personalized medicine	167
Diseases due to misfolding of proteins	167
<i>Therapies for protein misfolding</i>	168
Significance of mitochondrial proteome in human disease	169
Proteomic technologies for drug discovery and development	169
Role of reverse-phase protein microarray in drug discovery.....	169
Role of proteomics in clinical drug safety.....	169
Toxicoproteomics	170
Application of pharmacoproteomics in personalized medicine	171
6. Role of Metabolomics in Personalized Medicine	172
Metabolomics and metabonomics	172
Metabolomics bridges the gap between genotype and phenotype	172
Metabolomics, biomarkers and personalized medicine	173
Metabolomic technologies.....	173
Urinary profiling by capillary electrophoresis.....	174
Lipid profiling	174
Role of metabolomics in biomarker identification and pattern recognition	175
Validation of biomarkers in large-scale human metabolomics studies.....	175
Pharmacometabonomics	175
Metabonomic technologies for toxicology studies	176
Metabonomics/metabolomics and personalized nutrition	176
7. Personalized Biological Therapies.....	178
Introduction.....	178
Recombinant human proteins	178
Therapeutic monoclonal antibodies	178
Cell therapy	179
Autologous tissue and cell transplants	179
Stem cells.....	179
<i>Role of stem cells derived from unfertilized embryos</i>	179
Cloning and personalized cell therapy	180
Use of stem cells for drug testing	180
Gene therapy	180
Personalized vaccines	181
Personalized vaccines for viral diseases	181
Personalized cancer vaccines	181
Antisense therapy	181
RNA interference.....	182
MicroRNAs.....	183
8. Personalized Medicine in Major Therapeutic Areas	184
Introduction.....	184
Management of infections.....	185
Management of HIV	185
<i>CD4 counts as a guide to drug therapy for AIDS</i>	185
<i>Drug-resistance in HIV</i>	185
<i>Genetics of human susceptibility to HIV infection</i>	186
<i>Measurement of Replication Capacity</i>	187
<i>Personalized vaccine for HIV</i>	187
<i>Prevention of adverse reactions to antiviral drugs</i>	187
<i>Pharmacogenetics and HIV drug safety</i>	188
<i>Pharmacogenomics of antiretroviral agents</i>	188
<i>Role of diagnostic testing in HIV</i>	189

<i>Role of genetic variations in susceptibility to HIV-1</i>	189
Personalized treatment of hepatitis B.....	189
Personalized treatment of hepatitis C	190
<i>Responders vs non-responders to treatment for hepatitis C</i>	190
<i>Drug resistance in hepatitis C</i>	191
Personalized management of tuberculosis	191
Psychiatric disorders	192
Psychopharmacogenetics	192
<i>COMT genotype and response to amphetamine</i>	193
<i>Genotype and response to methylphenidate in children with ADHD</i>	193
Personalized antipsychotic therapy	193
Personalized antidepressant therapy.....	196
<i>EEG to predict adverse effects and evaluate antidepressant efficacy</i>	196
<i>Individualization of SSRI treatment</i>	197
<i>Vilazodone with a test for personalized treatment of depression</i>	198
Neurological disorders	198
Personalized management of Alzheimer's disease.....	198
Personalized management of Parkinson's disease.....	200
<i>Discovery of subgroup-selective drug targets in PD</i>	200
Personalized management of Epilepsy	201
<i>Choice of the right AED</i>	201
<i>Pharmacogenetics of epilepsy</i>	201
<i>Pharmacogenomics of epilepsy</i>	202
<i>Drug resistance in epilepsy</i>	202
<i>Future prospects for management of epilepsy</i>	204
Personalized management of migraine.....	204
<i>Individualization of use of triptans for migraine</i>	205
Personalized management of stroke	205
<i>Brain imaging in trials of restorative therapies for stroke</i>	206
<i>Decisions for evacuation of intracerebral hemorrhage</i>	206
<i>Revascularization procedures in chronic post-stroke stage</i>	206
Personalized treatment of multiple sclerosis	207
<i>Immunopathological patterns of demyelination for assessing therapy</i>	207
<i>Personalizing mitoxantrone therapy of multiple sclerosis</i>	208
<i>Fusokine method of personalized cell therapy of multiple sclerosis</i>	208
<i>MBP8298</i>	209
<i>Pharmacogenomics of IFN-β therapy in multiple sclerosis</i>	209
<i>T cell-based personalized vaccine for MS</i>	210
Cardiovascular disorders	210
Role of diagnostics in personalized management of cardiovascular disease.....	211
<i>Testing in coronary heart disease</i>	211
<i>SNP genotyping in cardiovascular disorders</i>	211
<i>Cardiovascular disorders with a genetic component</i>	212
<i>Gene variant as a risk factor for sudden cardiac death</i>	213
<i>KIF6 gene test as a guide to management of heart disease</i>	214
<i>SNP Chip for study of cardiovascular diseases</i>	214
Pharmacogenomics of cardiovascular disorders.....	215
Modifying the genetic risk for myocardial infarction	215
Management of heart failure.....	215
<i>β-blockers</i>	215
<i>Bucindolol</i>	216
<i>BiDil</i>	216
Management of hypertension.....	217
<i>Pharmacogenomics of diuretic drugs</i>	217
<i>Pharmacogenomics of ACE inhibitors</i>	218
<i>Management of hypertension by personalized approach</i>	218
<i>Prediction of antihypertensive activity of rosfafuroxin</i>	219
Pharmacogenetics of lipid-lowering therapies.....	219
<i>Polymorphisms in genes involved in cholesterol metabolism</i>	220
<i>Role of eNOS gene polymorphisms</i>	220
<i>The STRENGTH study</i>	221
<i>Personalized management of women with hyperlipidemia</i>	222
Thrombotic disorders.....	222
<i>Factor V Leiden mutation</i>	222
<i>Anticoagulant therapy</i>	223
<i>Antiplatelet therapy</i>	223
Nanotechnology-based personalized therapy of cardiovascular diseases.....	224
Project euHeart for personalized management of heart disease.....	224
Concluding remarks.....	225
Personalized management of pulmonary disorders.....	225
Role of genetic ancestry in lung function	225

Personalized therapy of asthma	225
<i>Biomarkers for predicting response to corticosteroid therapy</i>	226
<i>Genetic polymorphism and response to β_2-adrenergic agonists</i>	226
<i>Genotyping in asthma</i>	226
<i>IgE as guide to dosing of omalizumab for asthma</i>	227
<i>Lebrikizumab for personalised treatment of asthma</i>	228
Personalized management of chronic obstructive pulmonary disease	228
Personalized management of skin disorders	229
Genetic testing for personalized skin care	229
Management of hair loss based on genetic testing	229
Personalized therapy of rheumatoid arthritis	230
DIATSTAT™ anti-cyclic citrullinated peptides in rheumatoid arthritis	230
Personalization of COX-2 inhibitor therapy	231
Personalization of infliximab therapy	231
Personalized approaches in immunology	231
Role of Mannose-binding lectin in personalized medicine	232
Pharmacogenetics and pharmacogenomics of immunosuppressive agents	232
Personalized management of patients with lupus erythematosus	233
Personalized management of pain	233
Pharmacogenetics/pharmacogenomics of pain	234
Mechanism-specific management of pain	235
Preoperative testing to tailor postoperative analgesic requirements	235
Personalized analgesics.....	236
Management of genetic disorders	236
Personalized treatment of cystic fibrosis.....	236
Personalized management of gastrointestinal disorders	237
Personalized therapy of inflammatory bowel disease	237
Personalized management of lactose intolerance	237
Personalized approaches to improve organ transplantation	238
Personalization of kidney transplantation	238
Personalization of cardiac transplantation	238
Prediction of rejection to tailor anti-rejection medications	239
Personalized immunosuppressant therapy in organ transplants	239
Role of immunological biomarkers in monitoring grafted patients	240
Improved matching of blood transfusion	241
Personalized approach to addiction	241
Pharmacogenetics of drug addiction	241
Genetic polymorphism and management of alcoholism	241
Personalized therapy for smoking cessation	242
<i>Antidepressant therapy for smoking cessation</i>	242
<i>Effectiveness of nicotine patches in relation to genotype</i>	243
Personalized approaches to miscellaneous problems	243
Hormone replacement therapy in women	243
Personalized treatment of malaria	243
Personalized management of renal disease.....	244
<i>Gene associated with end-stage renal disease</i>	244
Personalized care of trauma patients	245
Personalized anticoagulation.....	245
Personalized Hyperbaric oxygen therapy	246
Personalized preventive medicine	246
Personalized nutrition	247
Nutrigenomics	247
<i>Genomics of vitamin D and calcium supplementation</i>	248
<i>Nutrigenomics and functional foods</i>	248
<i>Nutrigenetics and personalized medicine</i>	249
<i>Nutrigenomics and personalized medicine</i>	249
Nutrition and proteomics.....	250
Personalized diet prescription	250
9. Personalized Therapy of Cancer	252
Introduction	252
Challenges of cancer classification.....	252
Relationships of technologies for personalized management of cancer	252
Impact of molecular diagnostics on the management of cancer	253
AmpliChip P53 as companion diagnostic for cancer	254
Analysis of RNA splicing events in cancer	254
Analysis of chromosomal alterations in cancer cells	254
Cancer classification using microarrays	255
Detection of loss of heterozygosity	256
Diagnosis of cancer of an unknown primary	256
Diagnostics for detection of minimal residual disease	256

DNA repair biomarkers	257
Fluorescent in situ hybridization	257
Gene expression profiling	257
Gene expression profiles predict chromosomal instability in tumors	259
Isolation and characterization of circulating tumor cells	259
Modulation of CYP450 activity for cancer therapy	260
Personalized therapies based on oncogenic pathways signatures	260
Quantum dot-based test for DNA methylation	261
Role of molecular imaging in personalized therapy of cancer	261
<i>Functional diffusion MRI</i>	261
<i>FDG-PET/CT for personalizing cancer treatment</i>	262
<i>Image-guided personalized drug delivery in cancer</i>	262
<i>Tumor imaging and elimination by targeted gallium corrole</i>	262
<i>Future prospects of molecular imaging in management of cancer</i>	263
Unraveling the genetic code of cancer	263
Cancer prognosis	263
<i>Detection of mutations for risk assessment and prevention</i>	264
Impact of biomarkers on management of cancer	265
HER-2/neu oncogene as a biomarker for cancer	265
L-asparaginase treatment of cancer guided by a biomarker	265
Oncogene GOLPH3 as a cancer biomarker	265
Predictive biomarkers for cancer	266
Sequencing to discover biomarkers to personalize cancer treatment	266
Systems biology approach to discovery of radiation sensitivity biomarkers	267
VeraTag™ assay system for cancer biomarkers	267
Determination of response to therapy	268
ChemoFx cell culture assay for predicting anticancer drug response	268
Ex vivo testing of tumor biopsy for chemotherapy sensitivity	268
Genomic approaches to predict response to anticancer agents	269
<i>Gene expression patterns to predict response of cancer to therapy</i>	269
<i>Genomic analysis of tumor biopsies</i>	269
<i>Genotype-dependent efficacy of pathway inhibition in cancer</i>	269
<i>Mutation detection at molecular level</i>	270
<i>Role of genetic variations in susceptibility to anticancer drugs</i>	270
Non-genetic factors for variations in response of cancer cells to drugs	270
Proteomic analysis of tumor biopsies to predict response to treatment	271
Real-time apoptosis monitoring	271
Serum nucleosomes as indicators of sensitivity to chemotherapy	271
Targeted microbubbles to tumors for monitoring anticancer therapy	272
PET imaging for determining response to chemotherapy	273
Tissue systems biology approach to personalized management of cancer	273
Targeted cancer therapies	273
Targeting glycoproteins on cell surface	273
Targeting pathways in cancer	274
Functional antibody-based therapies	274
Personalized cancer vaccines	275
Antigen-specific vaccines	276
<i>Active immunotherapy based on antigen specific to the tumor</i>	276
Tumor-derived vaccines	276
<i>MyVax</i>	277
<i>OncoVAX</i>	277
<i>Tumor cells treated with dinitrophenyl</i>	277
<i>Prophage</i>	278
<i>Melacine</i>	278
Patient-specific cell-based vaccines	278
<i>Dendritic cell-based vaccines</i>	278
Adoptive cell therapy	280
<i>Combination of antiangiogenic agents with ACT</i>	281
<i>Genetically targeted T cells for treating B cell malignancies</i>	282
<i>Genetic engineering of tumor cells</i>	282
<i>Hybrid cell vaccination</i>	282
Personalized peptide cancer vaccines	283
Current status and future prospects of personalized cancer vaccines	283
Personalized radiation therapy	285
Molecular diagnostics combined with cancer therapeutics	286
Aptamers for combined diagnosis and therapeutics of cancer	286
Role of nanobiotechnology in personalized management of cancer	287
Design of future cancer therapies	287
Screening for personalized anticancer drugs	288
Role of epigenetics in development of personalized cancer therapies	288
Personalized therapy of cancer based on cancer stem cells	288

Role of oncoproteomics in personalized therapy of cancer	289
Cancer tissue proteomics	289
Role of sequencing in personalized therapy of cancer.....	290
Pharmacogenomic-based chemotherapy.....	290
Whole genome technology to predict drug resistance.....	290
Anticancer drug selection based on molecular characteristics of tumor.....	290
Testing microsatellite-instability for response to chemotherapy.....	291
Pharmacogenetics of cancer chemotherapy	291
CYP 1A2.....	292
Thiopurine methyltransferase	292
Dihydropyrimidine dehydrogenase	293
UGT1A1 test as guide to irinotecan therapy	293
Role of computational models in personalized anticancer therapy.....	294
A computational model of kinetically tailored treatment	294
Mathematical modeling of tumor microenvironments	294
Molecular profiling of cancer.....	295
Drug resistance in cancer	295
Detection of drug resistance in cancer by metabolic profiling	296
Determination of chemotherapy response by topoisomerase levels.....	296
<i>Anaplastic lymphoma kinase</i>	296
Management of drug resistance in leukemia	297
Overexpression of multidrug resistance gene.....	297
P53 mutations	298
A chemogenomic approach to drug resistance	298
Systems biology approach to personalizing therapy for drug-resistant cancer	298
Examples of personalized management of cancer.....	299
Personalized management of brain cancer.....	299
<i>Biosimulation approach to personalizing treatment of brain cancer</i>	299
<i>Genetics and genomics of brain cancer</i>	299
<i>Prognosis of glioblastoma multiforme based on its genetic landscape</i>	301
<i>Molecular diagnostics for personalized management of brain cancer</i>	301
<i>Personalized chemotherapy of brain tumors</i>	303
<i>Personalized therapy of oligodendroglial tumors (OTs)</i>	304
<i>Personalized therapy of neuroblastomas</i>	304
<i>Personalized therapy of medulloblastomas</i>	305
<i>Personalized management of germ cell brain tumors</i>	306
Personalized management of breast cancer	306
<i>Developing personalized drugs for breast cancer</i>	306
<i>Gene expression plus conventional predictors of breast cancer</i>	307
<i>Her2 testing in breast cancer as a guide to treatment</i>	308
<i>HER2/neu-derived peptide vaccine for breast cancer</i>	310
<i>Molecular diagnostics in breast cancer</i>	310
<i>Pharmacogenetics of breast cancer</i>	311
<i>Proteomics-based personalized management of breast cancer</i>	311
<i>Predicting response to chemotherapy in breast cancer</i>	312
<i>Prediction of resistance to chemotherapy in breast cancer</i>	315
<i>Prediction of adverse reaction to radiotherapy in breast cancer</i>	316
<i>Prediction of recurrence in breast cancer for personalizing therapy</i>	316
<i>Prognostic tests for breast cancer</i>	317
<i>Racial factors in the management of breast cancer</i>	319
<i>RATHER consortium to study personalized approach to breast cancer</i>	320
<i>TAILORx (Trial Assigning Individualized Options for Treatment)</i>	320
<i>Trends and future prospects of breast cancer research</i>	321
<i>Understanding tumor diversity in mouse mammary cancer model</i>	321
Personalized management of ovarian cancer	321
<i>Early diagnosis of ovarian cancer</i>	321
<i>Determining response to chemotherapy in ovarian cancer</i>	322
<i>Recurrent and drug-resistant ovarian cancer</i>	322
<i>Pathway targeted therapies for ovarian cancer</i>	323
Personalized management of hematological malignancies	324
<i>Personalized management of acute lymphoblastic leukemia</i>	324
<i>Personalized management of acute myeloid leukemia</i>	325
<i>Personalized management of chronic lymphocytic leukemia</i>	326
<i>Personalized management of multiple myeloma</i>	326
<i>Personalized management B cell lymphomas</i>	327
<i>Personalized vaccine for follicular lymphoma</i>	328
<i>Personalized management of myelodysplastic syndrome</i>	328
Personalized management of hepatocellular carcinoma	329
Personalized management of gastrointestinal cancer	329
<i>Personalized management of esophageal cancer</i>	329
<i>Personalized management of gastric cancer</i>	330

<i>Personalized management of colorectal cancer</i>	330
<i>A systems biology approach to drug resistance in colorectal cancer</i>	333
Personalized management of liver cancer	333
Personalized management of lung cancer	334
<i>Determination of outcome of EGFR tyrosine kinase inhibitor treatment</i>	334
<i>Crizotinib for personalized management of NSCLC</i>	336
<i>Testing for response to chemotherapy in lung cancer</i>	336
<i>Testing for prognosis of lung cancer</i>	337
<i>Testing for recurrence of lung cancer</i>	337
<i>Role of a new classification system in the management of lung cancer</i>	337
<i>Personalized therapy of NSCLC based on KIF5B/RET fusion oncogene</i>	337
Personalized management of malignant melanoma	338
<i>Therapy for inhibiting BRAF mutation in melanoma</i>	338
<i>Vaccine for malignant melanoma based on heat shock protein</i>	339
Personalized management of pancreatic cancer	339
<i>Biomarkers of pancreatic cancer</i>	339
<i>Histone modifications predict treatment response in pancreatic cancer</i>	340
Personalized management of prostate cancer	340
<i>Diagnostics for guiding therapy of prostate cancer</i>	340
<i>Early detection of cancer recurrence and guiding treatment</i>	341
<i>Effects of lifestyle changes shown by gene expression studies</i>	341
<i>Personalized peptide vaccine for prostate cancer</i>	342
Future of cancer therapy	342
Challenges for developing personalized cancer therapies.....	342
Cancer Genome Atlas	343
COLTHERES consortium	343
Computer and imaging technologies for personalizing cancer treatment.....	343
Genomic Cancer Care Alliance	344
Integrated genome-wide analysis of cancer for personalized therapy.....	344
International Cancer Genome Consortium	344
PREDICT Consortium	345
Companies involved in developing personalized cancer therapy	346

10. Development of Personalized Medicine..... 349

Introduction	349
Non-genomic factors in the development of personalized medicine	349
Personalized medicine based on circadian rhythms.....	349
Cytomics as a basis for personalized medicine	350
Intestinal microflora	350
<i>Gut microbiome compared to human genome</i>	350
<i>Metabolic interactions of the host and the intestinal microflora</i>	351
Role of drug delivery in personalized medicine.....	351
Personalized approach to clinical trials	352
<i>Use of Bayesian approach in clinical trials</i>	352
<i>Individualizing risks and benefits in clinical trials</i>	352
<i>Clinical trials of therapeutics and companion diagnostics</i>	353
Players in the development of personalized medicine	353
Personalized Medicine Coalition.....	353
<i>European Personalized Medicine Diagnostics Association</i>	354
Role of pharmaceutical industry	355
<i>Production and distribution of personalized medicines</i>	355
Role of biotechnology companies	356
Role of life sciences industries	356
Role of molecular imaging in personalized medicine.....	357
<i>Molecular imaging for personalized drug development in oncology</i>	357
<i>Molecular imaging and CNS drug development</i>	359
<i>Companies involved in molecular imaging</i>	360
Role of the clinical laboratories	360
Role of the US government in personalized medicine	361
<i>Department of Health and Human Services and personalized medicine</i>	362
<i>Agency for Healthcare Research and Quality</i>	362
<i>Comparative effectiveness research</i>	363
Role of the US Government agencies in personalized medicine	364
<i>NIH's Roadmap Initiative for Medical Research</i>	365
<i>NIH and personalized medicine</i>	365
<i>NIH collaboration with the FDA</i>	366
<i>NIH and Genetic Testing Registry</i>	366
<i>National Institute of General Medical Sciences</i>	366
<i>National Institute of Standards and Technology</i>	368
<i>Role of the Centers for Disease Control</i>	369
Role of academic institutions in the US and Canada.....	369

<i>Clinical Proteomics Program of NCI & FDA</i>	369
<i>Coriell Personalized Medicine Collaborative™</i>	369
<i>Delaware Valley Personalized Medicine Project</i>	370
<i>Duke University Medical Center and genomic medicine</i>	370
<i>Evaluation of genetic tests and genomic applications</i>	371
<i>Ignite Institute</i>	372
<i>Indiana University Institute for Personalized Medicine</i>	372
<i>Institute of Medicine's role in personalized medicine</i>	372
<i>Jackson Laboratory for Genomic Medicine</i>	373
<i>Johns Hopkins Center for Personalized Cancer Medicine Research</i>	373
<i>Mayo Clinic's Center for Individualized Medicine</i>	373
<i>Mt. Sinai Medical Center's Personalized Medicine Research Program</i>	374
<i>Personalized medicine at Ontario Institute for Cancer Research</i>	374
<i>Personalized oncology at Massachusetts General Hospital</i>	376
<i>Personalized oncology at Oregon Health & Science University</i>	376
<i>Pharmacogenetics Research Network and Knowledge Base</i>	376
<i>Quebec Center of Excellence in Personalized Medicine</i>	377
<i>Southeast Nebraska Cancer Center's Personalized Medicine Network</i>	377
<i>Stanford Center for Genomics and Personalized Medicine</i>	377
<i>UNC Institute for Pharmacogenomics and Individualized Therapy</i>	377
<i>Wisconsin Genomics Initiative</i>	378
Role of academic collaborations with companies	378
<i>New York Genome Center</i>	378
Role of healthcare organizations and hospitals	379
<i>Signature Genetics</i>	379
Role of the medical profession	379
<i>The American Medical Association and personalized medicine</i>	379
<i>Education of the physicians</i>	380
<i>Off-label prescribing and personalized medicine</i>	380
<i>Medical education</i>	380
Public attitude towards personalized medicine	381
Role of genetic banking systems and databases	381
Role of biobanks in development of personalized medicine	382
UK Biobank	382
Biobanking and development of personalized medicine in EU	382
CARTaGENE for biobanks in Canada	383
Personalized medicine based on PhysioGenomics™ technology	383
Role of bioinformatics in development of personalized medicine	384
Exploration of disease-gene relationship	385
Biosimulation techniques for developing personalized medicine	385
Health information management	386
<i>Electronic health records</i>	386
<i>Linking patient medical records and genetic information</i>	387
<i>Management of personal genomic data</i>	388
<i>Use of EMRs for genetic research</i>	388
Personalized prognosis of disease	389
Integration of technologies for development of personalized medicine	389
Global scope of personalized medicine	390
Personalized medicine in the developed countries	390
<i>Personalized medicine in the US</i>	390
<i>Personalized medicine in the EU</i>	390
<i>UK National Health Service and medical genetics</i>	391
<i>Personalized medicine in Germany</i>	392
Personalized medicine in the developing countries	392
Advantages and limitations of personalized medicine	393
Limitations of personalized medicine	394
Future of personalized medicine	395
Ongoing genomic projects	395
<i>Understanding the genetic basis of diseases</i>	395
<i>Personal Genome Project</i>	395
<i>Genome-wide association studies</i>	396
<i>The 1000 Genomes Project</i>	397
<i>Genomics of aging in a genetically homogeneous population</i>	397
Translational science and personalized medicine	397
<i>Translation of genomic research into genetic testing for healthcare</i>	398
<i>Long-term behavioral effects of personal genetic testing</i>	398
Personalized predictive medicine	399
Opportunities and challenges	400
<i>Prospects and limitations of genetic testing</i>	400
<i>Genetic testing and concerns about equality of healthcare</i>	401
<i>Pharmacotyping</i>	401

Comparative-effectiveness research and personalized medicine	401
Medicine in the year 2015	402
Concluding remarks about the future of personalized medicine	402
11. Ethical and Regulatory Aspects of Personalized Medicine	405
Introduction to ethical issues	405
Ethical issues of pharmacogenetics.....	405
Ethical aspects of genetic information	405
Ethical issues of whole genome analysis.....	405
Ethical aspects of direct-to-consumer genetic services	406
Privacy issues in personalized medicine	407
Genetic Information Nondiscrimination Act in the US	408
Genotype-specific clinical trials	408
Social issues in personalized medicine	408
Race and personalized medicine.....	409
Regulatory aspects	410
CLSI guideline for the use of RNA controls in gene expression assays	411
MicroArray Quality Control Project.....	411
Regulatory aspects of pharmacogenetics	412
Regulation of direct-to-consumer genetic testing	413
Need for regulatory oversight of DTC.....	413
FDA and pharmacogenomics.....	416
FDA guidance for pharmacogenomic data submissions	416
Joint guidelines of the FDA and EU regulators for pharmacogenomics	417
Pharmacogenomic/pharmacogenetic information in drug labels.....	417
FDA guidelines for pharmacogenomics-based dosing	418
FDA and validation of biomarkers.....	418
FDA and predictive medicine.....	419
FDA regulation of multivariate index assays.....	419
Evaluation of companion diagnostics/therapeutic	421
12. Commercial Aspects of Personalized Medicine	423
Introduction.....	423
Perceived financial concerns	423
Personalized medicine and orphan drug syndrome	423
Commercial aspects of pharmacogenomics	423
Cost of DNA testing	423
Cost of sequencing the human genome.....	424
Cost of genotyping	426
Cost of pharmacogenomics-based clinical trials.....	426
Business development of pharmacogenomic companies	427
Cost of personalized healthcare	427
The rising healthcare costs in the US	427
Reducing healthcare costs by combining diagnostics with therapeutics.....	428
Cost-effectiveness of pharmacogenetic testing	428
Cost-effectiveness of CYP genotyping-based pharmacotherapy	429
Cost effectiveness of HIV genotyping in treatment of AIDS.....	429
Cost-effectiveness of warfarin pharmacogenomics.....	430
Lowering the high costs of cancer chemotherapy	430
Overall impact of personalized medicine on healthcare	431
Drivers for the development of personalized medicine	431
Evolution of medicine as a driver for personalized therapy markets	431
Collaboration between the industry and the academia	432
Personalized medicine and drug markets.....	433
Impact on drug markets	433
Growth of markets relevant to personalized medicine	434
SNP market.....	434
Pharmacogenomics	434
Pharmacogenetics	434
Pharmacoproteomics	435
Biochips.....	435
Point-of-Care.....	435
Markets for personalized medicines according to therapeutic areas.....	435
Markets for personalized medicines according to geographical regions	436
Market opportunities for personalization of medicine	436
Impact of personalized medicine on other industries.....	436
Strategies for developing and marketing personalized medicine	437
Education of the public	438
Role of the Internet in development of personalized medicine.....	438
Marketing companion diagnostics for personalized medicine	439

Tables

Table 1-1: Selected terms relevant to the concept of personalized medicine 22

Table 1-2: Landmarks in the historical development of personalized medicine 23

Table 1-3: Genetic variations in the human genome 28

Table 2-1: Molecular diagnostic technologies used for personalized medicine 46

Table 2-2: Applications of biochip technology relevant to personalized medicine 65

Table 2-3: Companies developing haplotyping technology 80

Table 2-4: Technologies for SNP analysis 80

Table 2-5: A sampling of companies involved in technologies for SNP genotyping 89

Table 2-6: Comparison of proteomic and genomic approaches in personalized medicine 97

Table 2-7: Selected methods for gene expression profiling 98

Table 2-8: A selection of companies with gene expression technologies 103

Table 2-9: Companies involved in companion diagnostics 107

Table 2-10: Applications of point-of-care diagnosis 108

Table 2-11: Companies developing point-of-care diagnostic tests 109

Table 2-12: Companies offering genetic screening tests directly to consumers 114

Table 3-1: Pharmacogenetic vs. pharmacogenomic studies 121

Table 3-2: Enzymes relevant to drug metabolism 123

Table 3-3: Examples of mutation of the enzyme CYP450 124

Table 3-4: Frequency distribution of drugs metabolized by major isoforms of CYP450. 124

Table 3-5: Commonly prescribed medications, which are metabolized by CYP2D6 124

Table 3-6: Polymorphisms in drug target genes that can influence drug response 130

Table 3-7: Effect of genetic polymorphisms on disease response to drugs 131

Table 3-8: Examples of genetically determined adverse reactions to drugs 134

Table 3-9: Examples of genotyping and phenotyping in some diseases 142

Table 3-10: Companies with novel molecular toxicology technology 144

Table 4-1: Role of pharmacogenomics in variable therapy targets 152

Table 4-2: Role of pharmacogenomics in clinical trials 155

Table 4-3: Examples of pharmacogenomics-based clinical studies 156

Table 4-4: Tumor suppressor genes, their chromosomal location, function and associated tumors. 159

Table 4-5: Gene polymorphisms relevant to cardiovascular disease management 160

Table 4-6: Companies involved in cardiovascular genomics 162

Table 4-7: A sampling of companies involved in neuropharmacogenomics 164

Table 8-1: Important therapeutic areas for personalized medicine 184

Table 8-2: Enzymes that metabolize antipsychotics 195

Table 8-3: Enzymes that metabolize antidepressants 196

Table 8-4: Biomarkers of response to interferon- β in multiple sclerosis 210

Table 8-5: Genes that cause cardiovascular diseases 212

Table 9-1: Factors that drive the development of personalized therapy in cancer 252

Table 9-2: Impact of molecular diagnostics on the management of cancer 253

Table 9-3: Targeted therapies in clinical use for cancer 274

Table 9-4: Clinical trials of personalized cancer vaccines 283

Table 9-5: Selected companies involved in developing personalized cancer therapies 346

Table 10-1: Players in the development of personalized medicine 353

Table 10-2: Members of the Personalized Medicine Coalition 354

Table 10-3: Biobanks relevant to personalized medicine 382

Table 10-4: Role of bioinformatics in the development of personalized medicine 384

Table 10-5: Advantages of personalized medicine for the biopharmaceutical industry 393

Table 10-6: Advantages of personalized medicine for the patients 393

Table 10-7: Advantage of personalized medicine for the physicians 393

Table 10-8: Advantage of personalized medicine for the healthcare providers 393

Table 10-9: Limitations of personalized medicine 394

Table 10-10: Methods of translational science that are relevant to personalized medicine 398

Table 10-11: Companies involved in predictive healthcare 399

Table 11-1: Drugs with genetic information in their labels 417

Table 12-1: Drivers for the development of personalized medicine 431

Table 12-2: Growth of markets relevant to personalized medicine 2011-2021 434

Table 12-3: Markets for personalized medicine according to therapeutic area 2011-2021 435

Table 12-4: Markets for personalized medicine in major regions 2011-2021 436

Table 12-5: Lack of efficacy in current therapy 436

Table 12-6: Impact of personalized medicine on other industries 437

Table 12-7: Strategies to develop personalized medicine 438

Table 12-8: Role of the Internet in development of personalized medicine 438

Figures

Figure 1-1: Relation of personalized medicine to other technologies	36
Figure 1-2: Relation of systems pharmacology to personalized medicine.....	42
Figure 2-1: Role of sequencing in personalized medicine.....	64
Figure 2-2: Role of biochips/microarrays in personalized medicine	66
Figure 2-3: Affymetrix GeneChip technology	67
Figure 2-4: Role of CYP450 genotyping in development of personalized medicine.....	68
Figure 2-5: Role of SNPs in personalized medicine	76
Figure 2-6: A scheme of integrated healthcare and personalized medicine	115
Figure 3-1: Pharmacogenetics as a link between genotype and phenotype	120
Figure 3-2: Role of pharmacogenetic technologies in personalized medicine	121
Figure 4-1: Impact of new technologies at various stages of the drug discovery process.....	154
Figure 4-2: Steps in the application of pharmacogenomics in clinical trials	156
Figure 7-1: Role RNAi in development of personalized medicine.....	182
Figure 8-1: A scheme of personalized approach to management of hypertension	218
Figure 8-2: A scheme of personalized management of pain.....	234
Figure 9-1: Relationships of technologies for personalized management of cancer	253
Figure 10-1: Integration of technologies for the development of personalized medicine	389
Figure 12-1: Evolution of personalized medicine as a market driver	432